Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia

Journal of Medical Virology

Volumn 85, Issue 7, 2013, Pages 1235-1241

  Oliveira, Ana ^a   Verdasca, Nuno ^a   Pista, Ângela ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

Cervical intraepithelial neoplasia; E6 E7 transcripts; HPV; MRNA testing

Indexed keywords

ONCOPROTEIN; VIRUS RNA;

ADULT; AGED; ARTICLE; ASSAY; CANCER SCREENING; CLART HUMAN PAPILLOMAVIRUS 2 ASSAY; CLINICAL EVALUATION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYBRID CAPTURE 2 TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; NUCLISENS EASYQ HPV ASSAY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS ONCOGENE; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; E6/E7 TRANSCRIPTS; HPV; MRNA TESTING;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; VIROLOGY; YOUNG ADULT;

EID: 84878232485     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23590     Document Type: Article

References (24)

1. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, Terrenato I, Ciccocioppo L, Frega A, Rossi P. 2011. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 49:2643-2650.
2. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers E-M. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79.
3. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snidjers PJ, Meijer CJ. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasias grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
4. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. 2011. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecol Oncol 120:430-438.
5. Clifford GM, Smith JS, Aguado T, Franceschi S. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 88:101-105.
6. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26:29-41.
7. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. 2009. Clinical performance of the APTIMA® HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 45:55-61.
8. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B. 2010. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ® HPV assay. J Clin Virol 47:177-181.
9. Jeantet D, Schwarzmann F, Tromp J, Melchers W, van der Wurff A, Oosterlaken T, Jacobs M, Troesch A. 2009. NucliSENS® EasyQ® HPV v1 test-Testing for oncogenic activity of human papillomaviruses. J Clin Virol 45:29-37.
10. Keegan H, Mc Inerney J, Pilkington L, Gronn P, Silva I, Karlsen F, Bolger N, Logan C, Furuberg L, O'Leary J, Martin C. 2009. Comparison of HPV detection technologies: Hybrid capture 2, PreTect™ HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods 155:61-66.
11. Kjaer SK, van der Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BI, Suntum M, Bock JE, Poll PA, Meijer CJ. 2002. Type-specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population-based prospective follow-up study. BMJ 325:572-576.
12. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M, Thoresen S. 2005. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 97:908-915.
13. Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch X, Cuzick J, Dillner J, Heideman DAM, Snidjers PJF. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years or older. Int J Cancer 124:516-520.
14. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, Skomedal H, Thoresen SO, Hagmar B. 2005. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 114:973-976.
15. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snidjers PJ, Meijer CJ. 2003. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
16. Pista A, Verdasca N, Oliveira A. 2011. Clinical performance of the CLART Human Papillomavirus 2 assay compared with the Hybrid Capture 2 test. J Med Virol 83:272-276.
17. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A. 2010. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 48:2779-2785.
18. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N, New Technologies for Cervical Cancer Screening Working Group. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100:492-501.
19. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907.
20. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121:621-632.
21. Sorbye SW, Fismen S, Gutteberg T, Mortensen ES. 2010. Triage of women with minor cervical lesions: Data suggesting a "Test and Treat" approach for HPV E6/E7 mRNA testing. PLoS ONE 5:e12724. DOI: 10.1371/journal.pone.0012724
22. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho I, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17:3033-3042.
23. Tropé A, Sjoborg K, Eskild A, Cuschieri K, Eriksen T, Thoresen S, Steinbakk M, Laurak V, Jonassen CM, Westerhagen U, Jacobsen MB, Lie AK. 2009. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol 47:2458-2464.
24. Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA. 2009. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1, 700 women referred to colposcopy in Oklahoma. Int J Cancer 124:964-969.